NEW YORK – Archeus Technologies on Friday said the US Food and Drug Administration cleared its investigational new drug application (IND) for the theranostic radiopharmaceutical agent ART-101 in ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

NEW YORK – Singapore's Ministry of Health announced this week it will launch a genetic testing program to improve diagnosis of familial hypercholesterolemia (FH) as part of a broader national focus on ...

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.

The US subsidiary will focus on advancing PolTreg's pipeline in these new territories, including its lead candidate PTG-007 in type 1 diabetes.